Martin Rosendale is a seasoned CEO in the biotechnology and medical device industries with over 30 years of experience leading successful product development and commercialization. Hands on management experience and passion for the human and business value of life sciences, biotechnology, healthcare and medical devices enables him, as an advisor and board member, to work through complexity toward insight and solutions–to grow businesses.
Martin has launched, branded, acquired and commercialized more than 10 products and companies. He has raised equity for public and private companies and non-dilutive capital through strategic partnerships. His experience spans public, private and not-for-profit businesses. He led a biotherapeutics company through a period of hyper growth taking the company from first sale to $200 million in annual revenue in three years. He worked with the Centers for Medicare and Medicaid Services to establish Medicare reimbursement for a complex product category. He also facilitated the merger of the two largest technology industry organizations in Maryland forming the Maryland Technology Council and strengthening its industry presence.
CEOs, Boards and investors that retain Martin, backed by the complementary, specialized expertise of partners at the Newport Board Group, get guidance and hands-on leadership for navigating complex business and organizational challenges—to grow and strengthen businesses in the life science, medical technology, and health care industries.